2026-10-19T00:02:19Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/122872026-10-18T21:14:18Zopenairedrivercom_ebyu_10000col_ebyu_10001

The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?De Simone, BelindaAbu-Zidan, Fikri M.Chouillard, ElieDi Saverio, SalomoneSartelli, MassimoPodda, MauroGomes, Carlos AugustoMoore, Ernest E.Moug, Susan J.Ansaloni, LucaKluger, YoramCoccolini, FedericoLandaluce-Olavarria, AitorEstraviz-Mateos, BegoñaUriguen-Etxeberria, AnaGiordano, AlessioLuna, Alfonso PalmieriAmín, Luz Adriana HernándezHernández, Adriana María PalmieriShabana, AmandaDzulkarnaen, Zakaria AndeeOthman, Muhammad AsyrafSani, Mohamad IkhwanBalla, AndreaScaramuzzo, RosaLepiane, PasqualeBottari, AndreaStaderini, FabioCianchi, FabioCavallaro, AndreaZanghì, AntonioCappellani, AlessandroCampagnacci, RobertoMaurizi, AngelaMartinotti, MarioRuggieri, AnnamariaJusoh, Asri CheRahman, Karim AbdulZulkifli, Anis Suraya M.Petronio, BarbaraMatías-García, BelénQuiroga-Valcárcel, AnaMendoza-Moreno, FernandoAtanasov, BoykoCampanile, Fabio CesareVecchioni, IlariaCardinali, LucaTravaglini, GraziaSebastiani, ElisaChooklin, SergeAcute cholecystitisCholecystectomyCOVID-19GangreneGangrenous cholecystitisLaparoscopyPandemicSARS-CoV-2SurgeryCholecystitisCholecystitis, AcuteFemaleHumansMaleMiddle AgedPandemicsPostoperative ComplicationsSepsishumanpostoperative complicationBackground: The incidence of the highly morbid and potentially lethal gangrenous cholecystitis was reportedly increased during the COVID-19 pandemic. The aim of the ChoCO-W study was to compare the clinical findings and outcomes of acute cholecystitis in patients who had COVID-19 disease with those who did not. Methods: Data were prospectively collected over 6 months (October 1, 2020, to April 30, 2021) with 1-month follow-up. In October 2020, Delta variant of SARS CoV-2 was isolated for the first time. Demographic and clinical data were analyzed and reported according to the STROBE guidelines. Baseline characteristics and clinical outcomes of patients who had COVID-19 were compared with those who did not. Results: A total of 2893 patients, from 42 countries, 218 centers, involved, with a median age of 61.3 (SD: 17.39) years were prospectively enrolled in this study; 1481 (51%) patients were males. One hundred and eighty (6.9%) patients were COVID-19 positive, while 2412 (93.1%) were negative. Concomitant preexisting diseases including cardiovascular diseases (p < 0.0001), diabetes (p < 0.0001), and severe chronic obstructive airway disease (p = 0.005) were significantly more frequent in the COVID-19 group. Markers of sepsis severity including ARDS (p < 0.0001), PIPAS score (p < 0.0001), WSES sepsis score (p < 0.0001), qSOFA (p < 0.0001), and Tokyo classification of severity of acute cholecystitis (p < 0.0001) were significantly higher in the COVID-19 group. The COVID-19 group had significantly higher postoperative complications (32.2% compared with 11.7%, p < 0.0001), longer mean hospital stay (13.21 compared with 6.51 days, p < 0.0001), and mortality rate (13.4% compared with 1.7%, p < 0.0001). The incidence of gangrenous cholecystitis was doubled in the COVID-19 group (40.7% compared with 22.3%). The mean wall thickness of the gallbladder was significantly higher in the COVID-19 group [6.32 (SD: 2.44) mm compared with 5.4 (SD: 3.45) mm; p < 0.0001]. Conclusions: The incidence of gangrenous cholecystitis is higher in COVID patients compared with non-COVID patients admitted to the emergency department with acute cholecystitis. Gangrenous cholecystitis in COVID patients is associated with high-grade Clavien-Dindo postoperative complications, longer hospital stay and higher mortality rate. The open cholecystectomy rate is higher in COVID compared with non -COVID patients. It is recommended to delay the surgical treatment in COVID patients, when it is possible, to decrease morbidity and mortality rates. COVID-19 infection and gangrenous cholecystistis are not absolute contraindications to perform laparoscopic cholecystectomy, in a case by case evaluation, in expert hands. Graphical abstract: [Figure not available: see fulltext.] © 2022, The Author(s).BioMed Central Ltd2022Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/12287https://doi.org/10.1186/s13017-022-00466-41749-7922enWorld Journal of Emergency Surgeryinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12287